FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135257055> ?p ?o ?g. }

• W2135257055 endingPage "43" @default.
• W2135257055 startingPage "32" @default.
• W2135257055 abstract "Purpose To evaluate the impact of supplemental external beam radiotherapy (EBRT) and/or androgen deprivation therapy (ADT) on 8-year biochemical outcome after permanent prostate brachytherapy. Methods and materials Between April 1995 and January 2001, 668 consecutive patients underwent brachytherapy using either 103Pd or 125I for clinical Stage T1b–T3aNxM0 (2002 American Joint Committee on Cancer) adenocarcinoma of the prostate gland. No patient underwent seminal vesicle biopsy or pathologic lymph node staging. The median follow-up was 58.6 months. Biochemical progression-free survival was defined by the American Society for Therapeutic Radiology and Oncology consensus definition. The clinical, treatment, and dosimetric parameters evaluated for biochemical progression-free survival included supplemental EBRT, ADT, patient age, clinical stage, Gleason score, preimplant prostate specific antigen (PSA), risk group, percentage of positive biopsies, isotope used, prostate volume, planning volume, percentage of target volume receiving 100%, 150%, and 200% of prescribed dose, minimal percentage of dose covering 90% of target volume, tobacco status, hypertension, and diabetes. Results For the entire group, the actuarial 8-year biochemical progression-free survival rate was 98.2%, 98.4%, and 88.2% for low-, intermediate-, and high-risk patients, respectively, with a median PSA level of <0.1 ng/mL for all risk groups and ADT and EBRT subgroups. At last follow-up, only 5 patients (0.8%) had died of metastatic prostate cancer. In multivariate analysis, Gleason score, percentage of positive biopsies, and ADT predicted for biochemical outcome in high-risk patients. In low- and intermediate-risk patients, none of the evaluated variables predicted for biochemical outcome. For the entire population, pretreatment PSA level, Gleason score, ADT, and clinical stage predicted for 8-year biochemical progression-free survival, with the percentage of positive biopsies approaching statistical significance. Conclusion Prostate brachytherapy results in a high probability of 8-year biochemical progression-free survival for low-, intermediate-, and high-risk patients. Although the role of supplemental EBRT could not be adequately evaluated in high-risk patients, it did not improve biochemical outcome in low- and intermediate-risk patients. However, ADT resulted in a statistically significant improvement in progression-free survival for high-risk patients." @default.
• W2135257055 created "2016-06-24" @default.
• W2135257055 creator A5017760305 @default.
• W2135257055 creator A5030939498 @default.
• W2135257055 creator A5040789807 @default.
• W2135257055 creator A5042090445 @default.
• W2135257055 creator A5046657217 @default.
• W2135257055 creator A5059064622 @default.
• W2135257055 date "2005-01-01" @default.
• W2135257055 modified "2023-10-07" @default.
• W2135257055 title "Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy" @default.
• W2135257055 cites W1594001332 @default.
• W2135257055 cites W1968819399 @default.
• W2135257055 cites W1975096840 @default.
• W2135257055 cites W1988456256 @default.
• W2135257055 cites W1994783923 @default.
• W2135257055 cites W2014250733 @default.
• W2135257055 cites W2021220421 @default.
• W2135257055 cites W2031877879 @default.
• W2135257055 cites W2038464364 @default.
• W2135257055 cites W2048579668 @default.
• W2135257055 cites W2059487933 @default.
• W2135257055 cites W2064057265 @default.
• W2135257055 cites W2065952940 @default.
• W2135257055 cites W2066582328 @default.
• W2135257055 cites W2082351586 @default.
• W2135257055 cites W2082943541 @default.
• W2135257055 cites W2086204317 @default.
• W2135257055 cites W2086342079 @default.
• W2135257055 cites W2092804733 @default.
• W2135257055 cites W2100773387 @default.
• W2135257055 cites W2122530789 @default.
• W2135257055 cites W2122815812 @default.
• W2135257055 cites W2125168442 @default.
• W2135257055 cites W2126645707 @default.
• W2135257055 cites W2129551651 @default.
• W2135257055 cites W2152171586 @default.
• W2135257055 cites W2153685427 @default.
• W2135257055 cites W2169594765 @default.
• W2135257055 cites W2171996164 @default.
• W2135257055 cites W2271151323 @default.
• W2135257055 cites W4294344900 @default.
• W2135257055 cites W92720502 @default.
• W2135257055 doi "https://doi.org/10.1016/j.ijrobp.2004.05.003" @default.
• W2135257055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15629591" @default.
• W2135257055 hasPublicationYear "2005" @default.
• W2135257055 type Work @default.
• W2135257055 sameAs 2135257055 @default.
• W2135257055 citedByCount "91" @default.
• W2135257055 countsByYear W21352570552012 @default.
• W2135257055 countsByYear W21352570552013 @default.
• W2135257055 countsByYear W21352570552014 @default.
• W2135257055 countsByYear W21352570552015 @default.
• W2135257055 countsByYear W21352570552016 @default.
• W2135257055 countsByYear W21352570552017 @default.
• W2135257055 countsByYear W21352570552018 @default.
• W2135257055 countsByYear W21352570552020 @default.
• W2135257055 crossrefType "journal-article" @default.
• W2135257055 hasAuthorship W2135257055A5017760305 @default.
• W2135257055 hasAuthorship W2135257055A5030939498 @default.
• W2135257055 hasAuthorship W2135257055A5040789807 @default.
• W2135257055 hasAuthorship W2135257055A5042090445 @default.
• W2135257055 hasAuthorship W2135257055A5046657217 @default.
• W2135257055 hasAuthorship W2135257055A5059064622 @default.
• W2135257055 hasConcept C121608353 @default.
• W2135257055 hasConcept C126322002 @default.
• W2135257055 hasConcept C126894567 @default.
• W2135257055 hasConcept C141071460 @default.
• W2135257055 hasConcept C143998085 @default.
• W2135257055 hasConcept C2775908122 @default.
• W2135257055 hasConcept C2775934546 @default.
• W2135257055 hasConcept C2776235491 @default.
• W2135257055 hasConcept C2777008409 @default.
• W2135257055 hasConcept C2777416452 @default.
• W2135257055 hasConcept C2777899217 @default.
• W2135257055 hasConcept C2779466945 @default.
• W2135257055 hasConcept C2780192828 @default.
• W2135257055 hasConcept C2781406297 @default.
• W2135257055 hasConcept C509974204 @default.
• W2135257055 hasConcept C71924100 @default.
• W2135257055 hasConceptScore W2135257055C121608353 @default.
• W2135257055 hasConceptScore W2135257055C126322002 @default.
• W2135257055 hasConceptScore W2135257055C126894567 @default.
• W2135257055 hasConceptScore W2135257055C141071460 @default.
• W2135257055 hasConceptScore W2135257055C143998085 @default.
• W2135257055 hasConceptScore W2135257055C2775908122 @default.
• W2135257055 hasConceptScore W2135257055C2775934546 @default.
• W2135257055 hasConceptScore W2135257055C2776235491 @default.
• W2135257055 hasConceptScore W2135257055C2777008409 @default.
• W2135257055 hasConceptScore W2135257055C2777416452 @default.
• W2135257055 hasConceptScore W2135257055C2777899217 @default.
• W2135257055 hasConceptScore W2135257055C2779466945 @default.
• W2135257055 hasConceptScore W2135257055C2780192828 @default.
• W2135257055 hasConceptScore W2135257055C2781406297 @default.
• W2135257055 hasConceptScore W2135257055C509974204 @default.
• W2135257055 hasConceptScore W2135257055C71924100 @default.
• W2135257055 hasIssue "1" @default.
• W2135257055 hasLocation W21352570551 @default.

• next